Alnylam Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ALNY and other ETFs, options, and stocks.

About ALNY

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. 

CEO
Yvonne L. Greenstreet
CEOYvonne L. Greenstreet
Employees
2,500
Employees2,500
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2002
Founded2002
Employees
2,500
Employees2,500

ALNY Key Statistics

Market cap
43.61B
Market cap43.61B
Price-Earnings ratio
141.12
Price-Earnings ratio141.12
Dividend yield
Dividend yield
Average volume
1.19M
Average volume1.19M
High today
$335.48
High today$335.48
Low today
$327.59
Low today$327.59
Open price
$332.54
Open price$332.54
Volume
662.39K
Volume662.39K
52 Week high
$495.55
52 Week high$495.55
52 Week low
$205.87
52 Week low$205.87

Stock Snapshot

With a market cap of 43.61B, Alnylam Pharmaceuticals(ALNY) trades at $328.73. The stock has a price-to-earnings ratio of 141.12.

As of 2026-04-02, Alnylam Pharmaceuticals(ALNY) stock has fluctuated between $327.59 and $335.48. The current price stands at $328.73, placing the stock +0.3% above today's low and -2.0% off the high.

The Alnylam Pharmaceuticals(ALNY)'s current trading volume is 662.39K, compared to an average daily volume of 1.19M.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $205.87.

In the last year, Alnylam Pharmaceuticals(ALNY) shares hit a 52-week high of $495.55 and a 52-week low of $205.87.

ALNY News

Simply Wall St 1d
Alnylam Data Update Highlights RNAi Potential And Undervalued Share Price

Alnylam Pharmaceuticals has reported new clinical and real world data on its RNAi therapy vutrisiran in ATTR-CM, highlighting durable benefits in quality of lif...

Alnylam Data Update Highlights RNAi Potential And Undervalued Share Price
TipRanks 2d
Alnylam’s DemonsTTRate Study: Real-World Data Could Shift the ATTR-CM Investment Story

Alnylam Pharmaceuticals (ALNY) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter, shar...

TipRanks 3d
Alnylam presents new data on potential of zilebesiran for hypertension

Alnylam (ALNY) presented pooled Phase 2 safety data for zilebesiran, an investigational RNAi therapeutic being evaluated for cardiovascular risk reduction in pa...

Analyst ratings

71%

of 28 ratings
Buy
71.4%
Hold
28.6%
Sell
0%

People also own

Based on the portfolios of people who own ALNY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.